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Immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis, psoriatic arthritis,
psoriasis, axial spondyloarthropathies, Crohn's disease, ulcerative colitis and juvenile idiopathic
arthritis, comprise a group of chronic disorders characterized by an immune-mediated pathogenesis.
Although at clinical presentation these diseases appear unrelated, they have been recognized to share
similar pathogenic mechanisms. Data from epidemiological and genetic studies further support the
concept that IMIDs are interrelated, as they can co-occur in the same patient and share a similar
genetic susceptibility. The specific aetiologies of IMIDs remain unknown, but all are known to involve
dysregulation of the immune system, including an over-expression of the pro-inflammatory cytokine
tumour necrosis factor (TNF). The pivotal role played by TNF in the pathogenesis and pathophysiology
of IMIDs has been documented by extensive preclinical and clinical investigations, and confirmed by
the efficacy of anti-TNF biotechnological drugs, such as etanercept, infliximab and adalimumab, in the
therapeutic management ofthese disorders. In this narrative review, we discuss the available data on the
TNF-dependent pathogenesis of IMIDs and associations among the different disorders. Although much
remains to be discovered about the pathogenesis and aetiology of IMIDs, their common inflammatory
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pathological features may explain why they can be successfully targeted by anti-TNF drugs. Among
these, adalimumab, a fully human monoclonal antibody, has been approved for treatment of nine distinct
IMID indications and it is likely to become a valuable therapeutic tool for this complex cluster of chronic
inflammatory disorders.
Immune-mediated inflammatory disease (lMID)
is a term used to describe a wide array of chronic
disorders resulting from an immune-mediated
inflammatory pathogenesis (I). Diseases such
as rheumatoid arthritis (RA), psoriatic arthritis
(PsA), psoriasis, axial spondyloarthropathies
(SpA), including pre-radiographic SpA and
ankylosing spondylitis (AS), juvenile idiopathic
arthritis (JIA), and inflammatory bowel diseases
(l8Ds), including Crohn's disease and ulcerative
colitis (UC), appear, on clinical presentation, to be
unrelated, as they display very different signs and
symptoms. However, they have been recognized
to share common pathogenic mechanisms. The
specific aetiologies leading to the onset of each of
these diseases remain unknown, and, therefore, it is
not clear whether the causative factors are similar
among the IMlDs. To date, risk factors for some
inflammatory diseases - including genetic and
environmental determinants - have been identified,
but whether the relationship is causal or not remains
to be established. For instance, environmental
factors implicated in IBDs include cigarette
smoking, appendectomy, urbanization, pollution,
diet, antibiotic use, hygiene status, socioeconomic
status and microbial exposure (2).
As IMlDs are all inflammatory conditions, it
is not unexpected that they share some common
pathological pathways, regardless of the specific
clinical presentation and underlying risk factors. In
particular, all involve dysregulation of the immune
system due to an imbalance or inappropriate release
of inflammatory cytokines such as interleukin
(lL)-12, IL-6 and tumour necrosis factor (TNF)
(I, 3, 4). The role of these cytokines has been
recognized as being pivotal in the pathogenesis and
pathophysiology of IMlDs, particularly TNF (5, 6).
This concept has been substantiated by the efficacy
of targeted biotechnological drugs - particularly
TNF inhibitors, such as etanercept, infliximab and
adalimumab, which have been shown to act as
modifiers of disease activity in the management
of a wide array of apparently clinically distinct
inflammatory disorders (3).
Epidemiological studies have revealed that the
overall prevalence of this cluster of inflammatory
diseases is approximately 4% of the US population
(approximately 12 million people) (7) and 5-7% of
Western populations (8), with prevalence rates of
individual diseases ranging from 0.04% to 8.5%,
depending on geographical and ethnic factors
(Table I; Figure I). Furthermore, the overall
prevalence of IMlDs is expected to increase as the
number of diseases classified as IMlDs grows (9).
Epidemiological data further support the concept
that IMlDs are interrelated and display disease co-
occurrence and associations (7). Recently, in addition
to the common pathological features, genome-wide
association studies have identified genes conferring
an increased risk of developing IMlDs, and have
highlighted a common background of genetic
susceptibility, which lends additional credibility
to the reported epidemiological evidence of a co-
occurrence (' genetic overlap ') of IMlDs (10-13).
Given the prevalence and association of IMIDs,
together with the substantial clinical morbidity,
disability, reduced quality of life (QoL) and lost
work productivity (14, 15), it is not surprising that
the socio-economic burden of these disorders is
quite high (4, 14-18).
Aim and methodology
The aim of this narrative review was to discuss
current data on TNF-mediated pathogenesis
of IMlDs and associations among the various
disorders. Combined literature searches were
performed on PubMed using the following search
terms: 'immune-mediated inflammatory disease/
disorder' AND 'tumour necrosis factor/TNF' AND
['rheumatoid arthritis' OR 'psoriatic arthritis' OR
'psoriasis' OR 'axial spondyloarthropathy' OR
'ankylosing spondylitis' OR 'Crohn's disease'
OR 'ulcerative colitis' OR 'juvenile idiopathic
arthritis'). Appropriate papers for this review were
selected manually from the search results and from
the bibliographies of previous review articles.
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TNF as a key factor in the pathogenesis of immune-
mediated diseases
TNF belongs to a large group of cytokines
collectively designated as the 'TNF superfamily',
which comprises cytokines that share molecular
and functional similarities. Besides TNF, the TNF
superfamily includes: lymphotoxins (comprising
lymphotoxin-a3 - previously designated as TNF-P
Iymphotoxin-ul liz and lymphotoxin-uzjll ); Fas (a
pro-apoptotic factor); CD40 (a factor regulating B
lymphocytes); receptor activator of nuclear factor
kappa-B. These cytokines are involved in the
regulation ofseveral steps ofthe biological processes
related to inflammatory and immune responses,
through the control of important cellular functions,
such as proliferation, differentiation, programmed
cell death (i.e. apoptosis) as well as the biosynthesis
and release of a wide array of molecular factors and
mediators (19, 20).
TNF is a pleiotropic cytokine deputed to regulate
a number of inflammatory reactions and immune
functions through the control of various cellular
processes, such as proliferation, differentiation,
apoptosis, and the release ofseveral molecular factors
(21). It is produced by a wide range of cell types,
including macrophages, T lymphocytes, mast cells,
granulocytes, NK (natural killer) cells, fibroblasts,
neurons, keratinocytes and smooth muscle cells
(19, 21). Biologically active TNF is a homotrimeric
molecular complex consisting of three identical
polypeptide subunits. Following biosynthesis, the
individual monomers are exposed on the surface of
Table 1. Prevalence ofimmune-mediated inflammatory diseases
Reference or source Disorder Country Prevalence
Robinson et al. (7) IMIDs US 4%
EI-Gabalawy et al. (8) IMIDs Western society 5-7%
Helmick et al. 2008 (59) RA US 1.3 million (0.4%)
Symmons et al. (60) RA UK I. 16% in women and
0.44% in men
Myasoedova et al. (61) RA US 0.72% in 2005, increased
from 0.62% in 1995
Helmick et al. 2008 (59) JIA US 294,000 (0.1%)
Helmick et al. 2008 (59) SpA US 0.6-2.4 million adults
(0.2-0.8%)
http://www.spondylitis.org/about/over Axial US 2.7 million (0.9%)
view.aspx spondyloarthri
tis
http://www.patient.co.ukldoctor/ankyl AS Worldwide 0.1-2% (higher in
osing-spondylitis Northern European
countries and lowest in
people of Afro-
Caribbean descent)
http://www.ccfa.org/what-are-crohns- IBD US 1.4 million (0.4%)
and-colitis/what-is-crohns-disease/ Crohn's 0.7 million (0.2%)
disease 0.7 million (0.2%)
UC
https://www.psoriasis.org/learn statisti Psoriasis US 7.5 million (2.2%)
cs
https://www.psoriasis.org/learn statisti Psoriasis Worldwide 125 million (2-3%)
cs
Parisi et al. (62) Psoriasis Worldwide From 0.91% (US) to
8.5% (Norway)
Gladman et al. (63) PsA Worldwide From 0.04% to 0.1%
AS, ankylosing spondylitis; IMID, immune-mediated inflammatory disease; JIA, juvenile idiopathic arthritis; RA, rheu-
matoid arthritis; SpA, spondyloarthropathy; UC, ulcerative colitis.
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Fig. 1. Prevalence ofRA, ISD and psoriasis.
cell membrane, where they are assembled to form
the membrane-bound homotrimeric transmembrane
TNF (tmTNF). tmTNF can then be cleaved by
TNF-a converting enzyme (TACE) to generate
the homotrimeric soluble form (sTNF), which is
released into the extracellular fluids and thereby into
the blood stream. TNF is biologically active in both
its trimeric forms - i.e. the membrane bound tmTNF
and the circulating sTNF. The monomeric form of
sTNF circulates also in the blood and, while it does
not appear to exert any biological activity as such,
it can assemble with other monomers to generate
biologically active trimeric sTNF complexes (21,
22).
TNF carries out its biological actions through
interaction with two specific receptors, designated
as TNF receptor I (TNFRI [p55, CDl20aD and
receptor 2 (TNFR2 [p75, CD 120bD. Both receptors
are trimeric glycoproteins localized on the cell
membrane surface, but they differ in terms ofcellular
expression, affinity for the different molecular forms
of TNF and transduction mechanisms. TNFR I
is constitutively expressed in the majority of cell
types, and displays preferential affinity for tmTNF.
TNFR2 expression is mainly inducible, particularly
in hematopoietic and endothelial cells , and has a
preferential affinity forsTNF (21, 23). tmTNF, owing
to its cell membrane location, can interact with target
cells equipped with TNF receptors and can exert a
dual action: on one hand it can stimulate cell surface
receptors on the target cell to elicit a biological
response in the target cell through the activation
of transduction pathways linked to the membrane
receptor (signalling); on the other hand, tmTNF itself
can be activated by its binding to the receptors on the
target cell (reverse signalling), thus becoming able
to mediate anti-inflammatory/immunomodulatory
actions, such as inhibition of T cell proliferation,
inhibition of pro-inflammatory cytokine release and
apoptosis. Of note, the anti-inflammatory responses
mediated by reverse signalling can be activated
also by binding of tmTNF with the large molecular
complexes generated by interaction of sTNF with
anti- TNF drugs, such as infliximab and adalimumab
(21,24).
TNF plays a central role in the pathogenesis
of most IMlDs (5) . Over-expression of TNF has
been shown indeed to promote pro-inflammatory
conditions. In particular, along with the dysregulation
of other cytokines and a variety of cell types, TNF is









Fig. 2. Schematic diagram showing the involvement of TNF in immune-mediated inflammatory disorders. Reproduced
with permission from Tracey D, et al. Pharmacol Ther 2008; 117:244-79 (21). FLlCE, FADD-like 1L-1fJ-converting en-
zyme; sTNF, soluble tumour necrosis factor; sTNFR1, soluble TNFR1; sTNFR2, soluble TNFR2; TACE, TNF alpha con-
verting enzyme; tmTNF, trans-membrane tumour necrosis factor; TNF, tumour necrosis factor; TNFR1, TNF receptor 1;
TNFR2, TNF receptor 2.
implicated in the pathogenesis ofRA, Crohn's disease,
psoriasis, PsA, systemic lupus erythematosus, type 1
diabetes, multiple sclerosis, asthma, allergy and UC
(3) (Figure 2).
Preclinical and clinical studies on RA have paved
the way towards our understanding of the pivotal role
played by TNF in the pathophysiology of IMIDs and
the identification of this inflammatory cytokine as a
relevant target for their therapeutic management (21).
The main pathologic hallmark ofRA is represented by
chronic synovial inflammation leading to progressive
joint cartilage and bone destruction. Studies aimed
at identifying the molecular pathogenesis of these
processes highlighted both TNF and IL-l as key
factors promoting inflammation and matrix disruption
(25, 26). It was then established that abnormal
elevations of TNF concentrations at the sites of
inflammation were a primary factor accounting for
the disease activity, and these observations generated
the hypothesis that the removal of TNF excess from
inflamed joints would have conferred therapeutic
benefits (27, 28). In support of these concepts,
transgenic mice over-expressing TNF were found to
spontaneously develop an arthritic pathology which
displayed clinical and histological features similar to
RA (29). Furthermore, in an experimental model of
collagen-induced arthritis, the blockade ofTNF was
effective in reducing the disease activity (30, 31).
A number of experimental and clinical studies
have provided compelling evidence to support a
strong role of TNF in the pathogenesis of IBDs (32,
33). The major findings in this field canbe concisely
summarized as follows: 1) elevated levels of TNF,
along with high concentrations of IL-l, transforming
growth factor-a and interferon-y, are present in the
inflamed mucosa of patients with Crohn's disease
(32); 2) there is an enhanced expression of TNF
in patients with both Crohn's disease and UC (34,
35); 3) studies in animals with experimental bowel
inflammation have shown that TNF functions as a
driving factor of disease activity (36, 37), and that
TNF inhibition or genetic suppression can prevent
disease onset and/or reduce disease severity (38).
TNF is involved in a number of mechanisms
underlying the pathogenesis of both psoriasis and
PsA (39). In the setting of psoriasis, the main TNF-
dependent mechanisms include: stimulation of
the maturation of Langerhans cells and dendritic
cells, with skewing of lymphocyte differentiation
(40); promotion of dendritic cell migration from
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the skin to lymph nodes (41, 42); accumulation of
leukocytes in the inflamed skin through induction
of adhesion molecules and chemokines on dennal
microvascular endothelial cells, keratinocytes, and
dermal fibroblasts (43, 44); induction of dermal
vascular changes via production of vascular
endothelial growth factor by keratinocytes and
hyperproliferation of keratinocytes (45); induction
of itching through the activation of TNF receptors
on sensory nerve endings (39). With regard for PsA,
TNF has been shown to playa primary role in the
determinism of inflammation and joint-bone damage
by virtue ofthe following mechanisms: production of
lytic enzymes, such as matrix metalloproteases (46);
contribution to synovial vascular proliferation by
induction of angiogenic growth factors; stimulation
of bone resorption, inhibition of bone formation,
and inhibition of synthesis of proteoglycans,
with subsequent occurrence of bone erosions up
to osteolysis, new bone deposition, or both; in
particular, based on evidence provided by preclinical
investigations, it has been appreciated that TNF
can promote osteoclastogenesis either directly, via
actions on osteoclast precursors and osteoclasts, or
indirectly, via induction of synovial inflammation
and various osteoclastogenic factors (39, 47, 48).
Inflammatory and autoimmune pathology
It is worth noting that several IMIDs also harbour
an autoimmune component. Indeed both autoimmune
diseases and IMIDs arise when adaptive and
innate immune system responses are impaired. An
autoimmune disease occurs when the organism fails
to recognize its own molecular components as self
constituents, thereby leading to an adaptive immune
response against its own cells and tissues. On the
other hand, an IMID results from a dysregulation
of the normal body's innate immune functions. An
inability to regulate the magnitude and duration
of the immune (or autoimmune) response leads to
the onset of an inflammatory state or a condition
of overreaction of the immune system. Subsequent
downstream signalling by proinflammatory
mediators, such as TNF, interleukins, interferons,
etc., gives rise, eventually, to the occurrence of
symptoms and end-organ damage. For instance, the
complex pathogenesis of IBOs, although not yet
completely elucidated, is known to involve both
auto-immune and immune-mediated mechanisms,
with a serious dysregulation of the innate immune
system, due to infection or trauma, leading to a
chronic inflammatory state and abnormalities of
the acquired immune system, which result in an
autoimmune response (49). In RA, besides the direct
targeting of synovial tissues by autoantibodies,
cytokines produced by synovial cells are thought to
be involved in the pathogenesis of the disease in its
early stage, and, in this context, TNF has been shown
to play a major positive feedback role through the
activation of cytokine and chemokine expression,
in combination with a plethora of other actions,
mediated by a variety ofcell receptors and molecular
factors, leading ultimately to RA clinical symptoms
and joint damage (50).
In diseases that appear to result from a combination
of both autoimmune and inflammatory pathogenic
mechanisms, it still remains unknown how the two
components interact or whether one can trigger and
maintain the other. Several autoimmune diseases do
not appear to be preceded by inflammation, although
some do, and many although not all autoimmune
diseases cause inflammation. Even though the same
mediators, including TNF, are often involved in
the pathogenesis of inflammation and autoimmune
responses, the relationship between these two
processes is far from clear. Indeed, autoimmunity
can, and often does occur in the absence of overt
inflammation, and vice versa, chronic inflammation
can exist in the absence of autoimmunity. The
picture is further complicated by the involvement of
other factors, such as environmental triggers, genetic
predisposition and comorbidities.
Associations of immune-mediated inflammatory dis-
eases
The contention of a common pathophysiology of
IMIDs is corroborated by the clinical evidence that,
often, two or more IMIOs co-exist in the same patient
(7). Certain diseases are more likely than others to
present in the same patient: these combinations are
designated as 'disease associations' - also termed
'immune-mediated inflammatory syndromes' or
'clustering' (3, 51, 52).
A large US-based epidemiological study has lent
support to the concept that IMIDs are interrelated
and has shown that a common pathogenic
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background translates into similar patterns ofdisease
co-occurrence, with patients affected by at least one
IMID having a higher risk of developing another
IMID (7). In addition, genome-wide association
studies have identified genes conferring an increased
risk of developing an IMID and have revealed a
common genetic susceptibility among IMIDs (10-
13).
Among the currently available TNF antagonists
- etanercept, infliximab, adalimumab, certolizumab
pegol and golimumab - adalimumab has been
approved for use in nine distinct IMID indications
(namely RA, PsA, SpA/AS, Crohn's disease,
paediatric Crohn's, UC, JIA, psoriasis and Behcet's
disease). Within these indications, the IMIDs that
have been found to occur in the same patient include:
RA + UC (53, 54); AS + Crohn's disease or UC (55);
PsA + psoriasis, Crohn's disease or UC (56); Crohn's
disease + psoriasis (56, 57); UC + psoriasis (58). In
these settings, the use of a multi-indication drug,
such as adalimumab, to treat two or more IMIDs in
the same patient, decreases the drug burden, thus
considerably making this TNF inhibitor a very useful
tool for the treatment of co-occurring IMIDs.
At present, the reasons for the occurrence of some
disease combinations and not others are not clear.
In addition, due to the above-mentioned genetic
susceptibility, IMIDs are also more likely to occur in
relatives of patients affected by an IMID (3).
CONCLUSIONS
Although much remains to be discovered about
the pathogenesis and aetiology of IMIDs, there is
presently clear evidence that these diseases share
similar pathological inflammatory pathways, and
that TNF represents one of the immune mediators
known to playa key role in their pathophysiology.
The common pathological background of IMIDs,
supported by their association in the same patient,
have been noted in clinical practice and confirmed
by epidemiological studies. Along the same lines,
genetic studies have also revealed common patterns
of genetic susceptibility. TNF is involved in a wide
array of biological activities including a number of
stimulating and inhibitory actions on several cellular
components within and outside the immune system,
resulting from molecular signalling and reverse
signalling mechanisms. The advances made in
understanding the role ofTNF in the pathophysiology
of chronic inflammatory disorders have led to the
development of biotechnological drugs acting
as TNF inhibitors, most of which are currently
employed for the therapeutic management of one or
more IMIDs. Among these, adalimumab has been
approved for the treatment of nine distinct IMID
indications and it is therefore expected to become a
valuable therapeutic tool across this complex cluster
of inflammatory disorders.
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